abstract |
Provided are a pyridopyrimidinone compound having a structure shown in general formula (II) and an application thereof. The compound can effectively inhibit KRAS G12C mutation, has the potential to be a drug for treating malignant tumors carrying KRAS G12C mutation (especially, non-small cell lung cancer (NSCLC) and colorectal cancer), and has great application value. |